VERSANT HCV RNA Qualitative Assay (TMA)
The VERSANT® HCV RNA Qualitative Assay* is based on state-of-the-art Transcription-Mediated Amplification (TMA) technology. TMA technology allows the VERSANT HCV RNA Qualitative Assay to provide maximum sensitivity for the detection of the hepatitis C virus (HCV) in infected patients.
*FDA, IVD. The most sensitive assay for detection of HCV currently approved by the U.S. FDA.
IVDD, CE Marked. This assay is used as an aid in the diagnosis of HCV infection, treatment monitoring and post treatment monitoring.
VERSANT is a registered trademark of Siemens. All other marks are the property of their respective owners.